Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study

Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, on if the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients are treated

Tags: ASH Conference CoverageMultiple Myeloma

Published: 07 December 2018

Recent Videos

video

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...

video

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...

video

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...

video

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...

video

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...

video

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...

video

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...

video

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...

video

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...

video

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...

Related Videos

video-image

Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019

video-image

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019

video-image

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

video-image

Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality

video-image

Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

video-image

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

video-image

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

video-image

Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study

video-image

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib

video-image

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

video-image

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

video-image

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019